Metformin anti-tumor effect via disruption of the MID1 translational regulator complex and AR downregulation in prostate cancer cells

Metformin is an approved drug prescribed for diabetes. Its role as an anti-cancer agent has drawn significant attention because of its minimal side effects and low cost. However, its mechanism of anti-tumour action has not yet been fully clarified. The effect on cell growth was assessed by cell coun...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BMC cancer 2014-01, Vol.14 (1), p.52-52, Article 52
Hauptverfasser:	Demir, Ummuhan, Koehler, Andrea, Schneider, Rainer, Schweiger, Susann, Klocker, Helmut
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Cell Movement - drug effects Cell Movement - physiology Down-Regulation - drug effects Down-Regulation - physiology Humans Kinases Male Metabolic disorders Metformin - pharmacology Metformin - therapeutic use Microtubule Proteins - antagonists & inhibitors Microtubule Proteins - genetics Microtubule Proteins - metabolism Nuclear Proteins - antagonists & inhibitors Nuclear Proteins - genetics Nuclear Proteins - metabolism Prostate cancer Prostatic Neoplasms - drug therapy Prostatic Neoplasms - genetics Prostatic Neoplasms - metabolism Receptors, Androgen - genetics Receptors, Androgen - metabolism Studies Transcription Factors - antagonists & inhibitors Transcription Factors - genetics Transcription Factors - metabolism Treatment Outcome Ubiquitin-Protein Ligases
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!